Skip to main content
. 2020 Jul 30;106(7):1892–1901. doi: 10.3324/haematol.2020.253781

Figure 2.

Figure 2.

Dynamics of hemophagocytic lymphohistiocytosis disease features during ruxolitinib treatment in eight patients who achieved complete response. (A) daily maximum temperature, within hours of receiving the first dose of ruxolitinib (RUX), most patient’s fever resolved; (B to D) The inflammatory markers soluble CD25 (sCD25), ferritin and interferon-γ (IFN-γ) cytokine level. Normal range values of sCD25, ferritin and IFN-γ are ≤6,400 pg/mL, ≤500 mg/L and ≤8 pg/mL respectively by the clinical laboratory; (E to G) absolute neutrophil count, hemoglobin concentration, absolute platelet count; (H) fibrinogen concentration; (I) triglyceride; (J) alanine aminotransferase (ALT) concentration. The dotted line on the x-axis of each graph indicate the start of RUX treatment.